According to univariate analysis, the on-treatment factors at 2 weeks after the start of sorafenib therapy significantly associated with worse OS were the absence of disappearance of arterial tumor enhancement on CE-CT (HR = 2.010; 95%CI, 1.099–3.673; p = 0.0233), AFP ratio of >1.2 (HR = 2.288; 95%CI, 1.196–4.386; p = 0.0123), and CP score elevation of ≥2 points (HR = 2.799; 95%CI, 1.216–6.440; p = 0.0155). The gene discussed is AFP; the disease is neoplasm.